• Aaron Neinstein

Another new basal insulin, degludec, is available in Japan

Japan has approved use of a new basal insulin from Novo Nordisk, insulin degludec.  It is being promoted by the company as having a duration of action up to 42 hours.  The press release is here.

#Diabetesmellitus #insulin #japan #novonordisk

0 views0 comments

Recent Posts

See All

Smart Insulin Pens are here… finally.

The first “smart” insulin pen has finally hit the market. This is a big moment for diabetes care, as the digital toolbox expands. (I wrote a post in 2013 about this topic, asking for someone to make a

  • Twitter
  • LinkedIn
  • Instagram

Dr. Aaron Neinstein is Associate Professor in the UCSF Division of Endocrinology and Director of Clinical Informatics at the UCSF Center for Digital Health Innovation, with a clinical practice focused on diabetes care. He is considered an expert in diabetes technology, including the use of insulin pumps and continuous glucose monitors, as a nationally-invited speaker and invited author to outlets like CNBC and Medscape, peer-reviewed author, and advisor to numerous companies.

© 2020 by Aaron Neinstein MD